| Literature DB >> 33787356 |
Yuyou Huang1,2, Fangfang Li1,2, Zhongyun Chen1, Weibi Chen1, Linlin Fan1, Yangmin Zheng2, Ziping Han1,2,3, Lingzhi Li1,2, Yumin Luo1,2,3,4, Yan Zhang1,4.
Abstract
Massive cerebral infarction (MCI) is a life-threatening disease and may lead to cerebral herniation. Neutrophil degranulation contributes to ischemic injury in the early stage. To investigate whether neutrophil degranulating factors can predict cerebral herniation and the long-term prognosis of patients with MCI and to investigate the relationship between neutrophil degranulation and blood brain barrier (BBB) damage. In this case-control study of 14 MCI patients, we divided the patients into a cerebral hernia group and no cerebral hernia group according to whether they developed cerebral herniation within 5 days. The prognosis of MCI patients was assessed using the Modified Rankin Scale (mRS) score at 6 months, which was the primary end point. The composition of white blood cells (WBC) and degranulating factors for neutrophils in the plasma of MCI patients was determined on days 2 and 4. Baseline characteristics were comparable in both groups. The neurological functional scores and long-term prognosis showed no difference between patients with or without cerebral herniation, while the mortality rate of the cerebral hernia group in the short term was higher (P < 0.05). The WBC count, neutrophil to lymphocyte ratio (NLR) and plasma myeloperoxidase (MPO) levels of patients with cerebral hernia were significantly higher than those of patients without cerebral hernia (all P < 0.05). MPO is a better predictor of cerebral herniation, and the NLR showed superior predictive value in the prognosis of MCI patients. neutrophil degranulation may play an important role in malignant cerebral hernia during MCI. These data suggest that, MPO and the NLR might be predictive factors for cerebral herniation and the prognosis of MCI patients.Entities:
Keywords: cerebral herniation; massive cerebral infarction; myeloperoxidase; neutrophil degranulation; neutrophil to lymphocyte ratio
Year: 2021 PMID: 33787356 PMCID: PMC8020096 DOI: 10.1177/09636897211004089
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064
Baseline Characteristics Between Patients with Cerebral Hernia and Without Cerebral Hernia.
| Parameters | Cerebral hernia ( | No cerebral hernia ( |
|
|---|---|---|---|
|
| |||
| Age | 53.60 ± 10.213 | 64.33 ± 10.247 | 0.922 |
| Sex (male) | 3 | 5 | 1.000 |
|
| |||
| Hypertension | 2 | 7 | 0.266 |
| Diabetes | 1 | 4 | 0.580 |
| Hyperlipidemia | 0 | 4 | 0.231 |
| Coronary artery disease | 0 | 2 | 0.505 |
| Atrial fibrillation | 1 | 1 | 0.504 |
| Heart failure | 1 | 0 | 0.164 |
| Previous stroke | 0 | 3 | 0.357 |
| Infection | 2 | 1 | 0.377 |
| Family history of stroke | 3 | 7 | 0.377 |
| Smoking | 3 | 3 | 0.537 |
| Drinking | 2 | 3 | 1.000 |
|
| |||
| Hemisphere (dominant) | 3 | 4 | 0.611 |
| Hemorrhage | 2 | 3 | 0.803 |
| NIHSS score on admission | 26.20 ± 8.635 | 21.56 ± 9.901 | 0.518 |
| Median | 22 | 16 | |
| Range | 12–37 | 11–40 | |
| Time from symptom onset to treatment start (h) | 3.51 ± 1.42 | 7.06 ± 3.78 | 0.041 |
| Median | 3.38 | 7.8 | |
| Range | 0.88–5.38 | 2.00–11.00 | |
|
| |||
| Intravenous rtPA | 3 | 1 | 0.091 |
| Arterial thrombolysis | 0 | 0 | 1.000 |
| Arterial thrombectomy | 4 | 2 | 0.009 |
| Arterial stent placement | 0 | 1 | 0.308 |
| Lowering intracranial pressure | 5 | 9 | 1.000 |
| Decompressive surgery | 0 | 4 | 0.0001 |
Figure 1.Neurological functional outcomes and survival rate of massive cerebral ischemic patients. (A) NHISS score and (B) GCS score of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 14 days after ischemia. (C) Survival rate of MCI patients with or without cerebral herniation at 6 months after ischemia. (D) mRS score of MCI patients with or without cerebral herniation at 6 months after ischemia (P > 0.05 compared to cerebral hernia group). GCS, Glasgow Coma Scale; MCI, Massive cerebral infarction; mRS. Modified Rankin Scale.
Figure 2.Composition of white blood cells in venous blood of MCI patients. (A) White blood cell count in venous blood of control group (n = 14) and MCI patients at 2 days after ischemia (n = 14). (B) White blood cell count in venous blood of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 2 days after ischemia. (C) Neutrophil to lymphocyte ratio in venous blood of control group (n = 14) and MCI patients at 2 days after ischemia (n = 14). (D) Neutrophil to lymphocyte ratio in venous blood of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 2 days after ischemia. (****P < 0.0001 compared to control group, ##p < 0.01 compared to cerebral hernia group). MCI, Massive cerebral infarction.
Figure 3.Neutrophil-activating factors in plasma of MCI patients. (A) Myeloperoxidase level in plasma of control group (n = 14) and MCI patients at 2 days after ischemia (n = 14). (B) Myeloperoxidase level in plasma of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 2 days after ischemia. (C) Correlations between myeloperoxidase levels in plasma and NIHSS score. (D) Neutrophil elastase level in plasma of control group (n = 14) and MCI patients at 2 days after ischemia (n = 14). (E) Neutrophil elastase level in plasma of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 2nd and 4th day after ischemia. (F) Correlations between neutrophil elastase levels in plasma and GCS score. MCI, Massive cerebral infarction.
Figure 4.Damage of BBB in MCI patients. (A) Cellular fibronectin level in plasma of control group (n = 14) and MCI patients at 2 days after ischemia (n = 14). (B) Cellular fibronectin level in plasma of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 2nd and 4th day after ischemia. (C) Neutrophil elastase level in plasma of control group (n = 14) and MCI patients at 2 days after ischemia (n = 14). (E) Neutrophil elastase level in plasma of MCI patients with cerebral herniation (n = 5) or without cerebral herniation (n = 9) at 2 days after ischemia. (F) Correlations between neutrophil elastase levels in plasma and GCS score. MCI, Massive cerebral infarction.
Figure 5.The ROC curves of the NLR and MPO levels in plasma of MCI patients. To evaluate the accuracy of the NLR and myeloperoxidase as risk factors that predict (A) cerebral herniation and (B) the prognosis of MCI patients. ROC= receiver operator characteristic (n = 14). MCI, Massive cerebral infarction; MPO, plasma myeloperoxidase; NLO, neutrophil to lymphocyte ratio.
Prediction of Cerebral Herniation Using the NLR and MPO Levels from MCI Patients Within 2 Days of Stroke Onset.
| Factors | AUC | 95% CI |
| Cutoff point | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
|
| 0.725 | 0.433–1.000 | 0.188 | 9.3953 | 80% | 62.50% |
|
| 0.9556 | 0.849–1.000 | 0.006 | 11.3001 | 100% | 77.80% |
Prediction of the Prognosis of MCI Patients Using the NLR and MPO Levels from MCI Patients Within 2 Days of Stroke Onset.
| Factors | AUC | 95% CI |
| Cutoff point | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
|
| 0.85 | 0.630–1.000 | 0.04 | 10.8278 | 75% | 100.00% |
|
| 0.825 | 0.573–1.000 | 0.057 | 11.3001 | 75% | 80.00% |
|
| 1.00 | 1.00–1.00 | 0.0027 | 0.5147 | 100% | 100% |